We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results , but sales fell by 1.6% year on year to $15.53 ...